CLINICAL DEVELOPMENT OF BIOLOGICS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION, 2003-2016

被引：0
|
作者：
Alexander, G. C. [1 ]
Ogasawara, K. [1 ]
Wiegand, D. [1 ]
Lin, D. H. [2 ]
Breder, C. D. [1 ]
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Drug Safety & Effectiveness, Baltimore, MD USA
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.1237
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP343
引用
收藏
页码：S209 / S209
页数：1
相关论文
共 50 条
  • [1] Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016
    G. Caleb Alexander
    Ken Ogasawara
    Dana Wiegand
    Dora Lin
    Christopher D. Breder
    Therapeutic Innovation & Regulatory Science, 2019, 53 : 752 - 758
  • [2] Clinical development of biologics approved by the US Food and Drug Administration, 2003-2016
    Alexander, G. Caleb
    Ogasawara, Ken
    Wiegand, Dana
    Lin, Dora H.
    Breder, Christopher D.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 476 - 476
  • [3] Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016
    Alexander, G. Caleb
    Ogasawara, Ken
    Wiegand, Dana
    Lin, Dora
    Breder, Christopher D.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2019, 53 (06) : 752 - 758
  • [4] PRICE ANALYSIS OF THERAPEUTIC BIOLOGICS APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (1986-OCTOBER 2015)
    Turkistani, F.
    Alotaibi, A.
    Alnafesah, A.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2016, 19 (03) : A271 - A272
  • [5] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Fei Liang
    Sheng Zhang
    Qin Wang
    Wenfeng Li
    BMC Cancer, 20
  • [6] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 486 - 492
  • [7] Clinical benefit of immune checkpoint inhibitors approved by US Food and Drug Administration
    Liang, Fei
    Zhang, Sheng
    Wang, Qin
    Li, Wenfeng
    BMC CANCER, 2020, 20 (01)
  • [8] Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
    Wallach, Joshua D.
    Luxkaranayagam, Anita T.
    Dhruva, Sanket S.
    Miller, Jennifer E.
    Ross, Joseph S.
    BMC MEDICINE, 2019, 17 (1)
  • [9] Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis
    Joshua D. Wallach
    Anita T. Luxkaranayagam
    Sanket S. Dhruva
    Jennifer E. Miller
    Joseph S. Ross
    BMC Medicine, 17
  • [10] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2020, 126 (19) : 4390 - 4399
12345